HK1256199A1 - Nrf2調節劑 - Google Patents
Nrf2調節劑Info
- Publication number
- HK1256199A1 HK1256199A1 HK18115299.6A HK18115299A HK1256199A1 HK 1256199 A1 HK1256199 A1 HK 1256199A1 HK 18115299 A HK18115299 A HK 18115299A HK 1256199 A1 HK1256199 A1 HK 1256199A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- nrf2 regulators
- nrf2
- regulators
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4192—1,2,3-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D267/02—Seven-membered rings
- C07D267/08—Seven-membered rings having the hetero atoms in positions 1 and 4
- C07D267/12—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
- C07D267/14—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with one six-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dermatology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562175505P | 2015-06-15 | 2015-06-15 | |
PCT/IB2016/053545 WO2016203401A1 (en) | 2015-06-15 | 2016-06-15 | Nrf2 regulators |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1256199A1 true HK1256199A1 (zh) | 2019-09-13 |
Family
ID=56178402
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK18115299.6A HK1256199A1 (zh) | 2015-06-15 | 2018-11-29 | Nrf2調節劑 |
Country Status (13)
Country | Link |
---|---|
US (2) | US10272095B2 (zh) |
EP (2) | EP3766878B1 (zh) |
JP (1) | JP6786527B2 (zh) |
KR (1) | KR20180018684A (zh) |
CN (1) | CN108137557B (zh) |
AU (1) | AU2016280236B2 (zh) |
BR (1) | BR112017027137A2 (zh) |
CA (1) | CA2988374A1 (zh) |
ES (2) | ES2910938T3 (zh) |
HK (1) | HK1256199A1 (zh) |
MA (1) | MA52032A (zh) |
RU (1) | RU2018101080A (zh) |
WO (1) | WO2016203401A1 (zh) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2018101080A (ru) | 2015-06-15 | 2019-07-15 | Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед | Регуляторы nrf2 |
SI3307739T1 (sl) | 2015-06-15 | 2021-03-31 | Glaxosmithkline Intellectual Property Development Limited | NRF2 regulatorji |
EP3371167A1 (en) * | 2015-10-06 | 2018-09-12 | GlaxoSmithKline Intellectual Property Development Limited | Arylcyclohexyl pyrazoles as nrf2 regulators |
US10364256B2 (en) | 2015-10-06 | 2019-07-30 | Glaxosmithkline Intellectual Property Development Limited | Biaryl pyrazoles as NRF2 regulators |
CN108779108A (zh) * | 2016-12-06 | 2018-11-09 | 葛兰素史密斯克莱知识产权发展有限公司 | 3-(2,3-二氢-1h-茚-5-基)丙酸衍生物和它们作为nrf2调节剂的用途 |
US11028099B2 (en) | 2016-12-15 | 2021-06-08 | Glaxosmithkline Intellectual Property Development Limited | NRF2 activators |
JP2020097526A (ja) * | 2017-03-28 | 2020-06-25 | 武田薬品工業株式会社 | 複素環化合物 |
WO2018211474A1 (en) | 2017-05-19 | 2018-11-22 | Trudell Medical International | Positive expiratory pressure device |
WO2019116231A1 (en) | 2017-12-11 | 2019-06-20 | Glaxosmithkline Intellectual Property Development Limited | Nrf2 activator for the treatment of acute lung injury, acute respiratory distress syndrome and multiple organ dysfunction syndrome |
USD903097S1 (en) | 2018-05-18 | 2020-11-24 | Trudell Medical International | Mask |
USD874064S1 (en) | 2018-05-18 | 2020-01-28 | Trudell Medical International | Mask |
JP2021524469A (ja) * | 2018-05-23 | 2021-09-13 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドGlaxosmithkline Intellectual Property Development Limited | Nrf2アクチベーターとしてのインダン |
USD893806S1 (en) | 2018-11-09 | 2020-08-18 | Trudell Medical Internationl | Mask and shroud |
AU2019391942B2 (en) | 2018-12-05 | 2024-03-21 | Scohia Pharma, Inc. | Macrocyclic compound and use thereof |
EP3924356A1 (en) * | 2019-02-15 | 2021-12-22 | GlaxoSmithKline Intellectual Property Development Ltd | Hydroxypyridoxazepines as nrf2 activators |
US20220259223A1 (en) | 2019-05-31 | 2022-08-18 | Ube Industries, Ltd. | Benzotriazole derivative |
CN113519459B (zh) * | 2021-06-11 | 2022-03-25 | 中国科学院合肥物质科学研究院 | 一种采用调节肝细胞ros水平的磁场发生装置在调节人/鼠肝细胞氧化应激中的应用 |
WO2023210741A1 (ja) * | 2022-04-28 | 2023-11-02 | 第一三共株式会社 | ベンゾトリアゾール化合物 |
Family Cites Families (53)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB348944A (en) * | 1930-07-05 | 1931-05-21 | Ig Farbenindustrie Ag | Improvements in the concentration of aqueous formic acid |
GB2064336B (en) | 1979-12-06 | 1984-03-14 | Glaxo Group Ltd | Device for dispensing medicaments |
DE3274065D1 (de) | 1981-07-08 | 1986-12-11 | Draco Ab | Powder inhalator |
US4778054A (en) | 1982-10-08 | 1988-10-18 | Glaxo Group Limited | Pack for administering medicaments to patients |
US4627432A (en) | 1982-10-08 | 1986-12-09 | Glaxo Group Limited | Devices for administering medicaments to patients |
GB2169265B (en) | 1982-10-08 | 1987-08-12 | Glaxo Group Ltd | Pack for medicament |
SE8603252L (sv) | 1985-07-30 | 1987-01-31 | Glaxo Group Ltd | Anordning for att tillfora lekemedel till patienter |
SK280968B6 (sk) | 1990-03-02 | 2000-10-09 | Glaxo Group Limited | Balenie medikamentu na použite v inhalačnom prístroji |
GB9004781D0 (en) | 1990-03-02 | 1990-04-25 | Glaxo Group Ltd | Device |
US6536427B2 (en) | 1990-03-02 | 2003-03-25 | Glaxo Group Limited | Inhalation device |
IL99537A (en) | 1990-09-27 | 1995-11-27 | Merck & Co Inc | Fibrinogen receptor antagonists and pharmaceutical preparations containing them |
US5217994A (en) | 1991-08-09 | 1993-06-08 | Merck & Co., Inc. | Method of inhibiting osteoclast-mediated bone resorption by administration of aminoalkyl-substituted phenyl derivatives |
KR100236806B1 (ko) | 1991-12-10 | 2000-01-15 | 시오노 요시히코 | 방향족 설폰아미드계 하이드록삼산 유도체 |
ES2186720T3 (es) | 1994-05-27 | 2003-05-16 | Merck & Co Inc | Composiciones para inhibir la reabsorcion osea mediada por osteoclastos. |
GB9700226D0 (en) | 1997-01-08 | 1997-02-26 | Glaxo Group Ltd | Inhalation device |
TWI262185B (en) | 1999-10-01 | 2006-09-21 | Eisai Co Ltd | Carboxylic acid derivatives having anti-hyperglycemia and anti-hyperlipemia action, and pharmaceutical composition containing the derivatives |
TWI284639B (en) | 2000-01-24 | 2007-08-01 | Shionogi & Co | A compound having thrombopoietin receptor agonistic effect |
WO2002059080A2 (en) | 2001-01-25 | 2002-08-01 | Guilford Pharmaceuticals Inc. | Trisubstituted carbocyclic cyclophilin binding compounds and their use |
JPWO2002080899A1 (ja) | 2001-03-30 | 2005-01-06 | エーザイ株式会社 | 消化器疾患治療剤 |
TWI311133B (en) | 2001-04-20 | 2009-06-21 | Eisai R&D Man Co Ltd | Carboxylic acid derivativeand the salt thereof |
TWI320039B (en) | 2001-09-21 | 2010-02-01 | Lactam-containing compounds and derivatives thereof as factor xa inhibitors | |
BRPI0212726B8 (pt) | 2001-09-21 | 2021-05-25 | Bristol Myers Squibb Co | compostos contendo lactamas, e derivados dos mesmos, composição farmacêutica que os compreende e seus usos |
US20040157919A1 (en) | 2002-01-25 | 2004-08-12 | Yong-Qian Wu | Trisubstituted carbocyclic cyclophilin binding compounds and their use |
GB0201677D0 (en) | 2002-01-25 | 2002-03-13 | Glaxo Group Ltd | Medicament dispenser |
WO2004007464A1 (ja) | 2002-07-10 | 2004-01-22 | Sumitomo Pharmaceuticals Co., Ltd. | イミダゾール誘導体 |
CA2520804A1 (en) | 2003-04-03 | 2004-10-28 | Merck & Co., Inc. | Biaryl substituted pyrazoles as sodium channel blockers |
WO2006044133A1 (en) | 2004-09-24 | 2006-04-27 | Axys Pharmaceuticals, Inc. | Active ketone inhibitors of tryptase |
EP1876179B1 (en) | 2005-04-28 | 2015-03-25 | Takeda Pharmaceutical Company Limited | Thienopyrimidone compounds |
GB0515584D0 (en) | 2005-07-28 | 2005-09-07 | Glaxo Group Ltd | Medicament dispenser |
AR058289A1 (es) | 2005-12-12 | 2008-01-30 | Glaxo Group Ltd | Colector para ser usado en dispensador de medicamento |
EP2037905B1 (en) | 2006-06-23 | 2013-05-01 | Radius Health, Inc. | Treatment of vasomotor symptoms with selective estrogen receptor modulators |
CA2698332C (en) | 2007-09-06 | 2012-08-21 | Merck Sharp & Dohme Corp. | Pyrazole derivatives as soluble guanylate cyclase activators |
JP2011527345A (ja) | 2008-07-07 | 2011-10-27 | ファスジェン, インコーポレイテッド | 新規な化合物、この化合物を含む医薬組成物、この化合物の使用方法、およびこの化合物の調製方法 |
JP5301652B2 (ja) | 2008-07-25 | 2013-09-25 | インフォコム株式会社 | 新規がん遺伝子nrf2 |
WO2010099054A2 (en) | 2009-02-26 | 2010-09-02 | Merck Sharp & Dohme Corp. | Soluble guanylate cyclase activators |
WO2011094890A1 (en) | 2010-02-02 | 2011-08-11 | Argusina Inc. | Phenylalanine derivatives and their use as non-peptide glp-1 receptor modulators |
WO2012068589A2 (en) | 2010-11-19 | 2012-05-24 | Constellation Pharmaceuticals | Modulators of methyl modifying enzymes, compositions and uses thereof |
US20140256767A1 (en) * | 2011-10-31 | 2014-09-11 | The Broad Institute, Inc. | Direct inhibitors of keap1-nrf2 interaction as antioxidant inflammation modulators |
US9382188B2 (en) | 2012-02-13 | 2016-07-05 | Takeda Pharmaceutical Company Limited | Aromatic ring compound |
WO2013155528A2 (en) | 2012-04-13 | 2013-10-17 | Fasgen, Inc. | Methods for reducing brain inflammation, increasing insulin sensitivity, and reducing ceramide levels |
WO2014145642A2 (en) * | 2013-03-15 | 2014-09-18 | The Johns Hopkins University | Nrf2 small molecule inhibitors for cancer therapy |
MX370410B (es) * | 2013-12-18 | 2019-12-11 | Glaxosmithkline Ip Dev Ltd | Reguladores de nrf2. |
EP3116862B1 (en) | 2014-03-10 | 2019-04-17 | Merck Sharp & Dohme Corp. | Piperazine derivatives as hiv protease inhibitors |
WO2015135091A1 (en) | 2014-03-10 | 2015-09-17 | Merck Sharp & Dohme Corp. | Piperazine derivatives as hiv protease inhibitors |
SI3307739T1 (sl) | 2015-06-15 | 2021-03-31 | Glaxosmithkline Intellectual Property Development Limited | NRF2 regulatorji |
CA2988373A1 (en) | 2015-06-15 | 2016-12-22 | Glaxosmithkline Intellectual Property Development Limited | Nrf2 regulators |
RU2018101080A (ru) | 2015-06-15 | 2019-07-15 | Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед | Регуляторы nrf2 |
EP3371167A1 (en) | 2015-10-06 | 2018-09-12 | GlaxoSmithKline Intellectual Property Development Limited | Arylcyclohexyl pyrazoles as nrf2 regulators |
US10364256B2 (en) | 2015-10-06 | 2019-07-30 | Glaxosmithkline Intellectual Property Development Limited | Biaryl pyrazoles as NRF2 regulators |
CN108779108A (zh) | 2016-12-06 | 2018-11-09 | 葛兰素史密斯克莱知识产权发展有限公司 | 3-(2,3-二氢-1h-茚-5-基)丙酸衍生物和它们作为nrf2调节剂的用途 |
WO2018109643A1 (en) | 2016-12-14 | 2018-06-21 | Glaxosmithkline Intellectual Property Development Limited | Bisaryl heterocycles as nrf2 acti |
ES2901617T3 (es) | 2016-12-14 | 2022-03-23 | Glaxosmithkline Ip Dev Ltd | Bisarilamidas como reguladores de NRF2 |
ES2848699T3 (es) | 2016-12-14 | 2021-08-11 | Glaxosmithkline Ip Dev Ltd | Compuestos de 3-oxo-1,4-diazepinilo como activadores de NRF2 |
-
2016
- 2016-06-15 RU RU2018101080A patent/RU2018101080A/ru not_active Application Discontinuation
- 2016-06-15 BR BR112017027137A patent/BR112017027137A2/pt active IP Right Grant
- 2016-06-15 AU AU2016280236A patent/AU2016280236B2/en not_active Ceased
- 2016-06-15 WO PCT/IB2016/053545 patent/WO2016203401A1/en active Application Filing
- 2016-06-15 CA CA2988374A patent/CA2988374A1/en not_active Abandoned
- 2016-06-15 US US15/735,977 patent/US10272095B2/en active Active
- 2016-06-15 EP EP20192327.3A patent/EP3766878B1/en active Active
- 2016-06-15 MA MA052032A patent/MA52032A/fr unknown
- 2016-06-15 JP JP2017564883A patent/JP6786527B2/ja active Active
- 2016-06-15 EP EP16731340.2A patent/EP3307729B1/en active Active
- 2016-06-15 CN CN201680047401.XA patent/CN108137557B/zh active Active
- 2016-06-15 ES ES20192327T patent/ES2910938T3/es active Active
- 2016-06-15 ES ES16731340T patent/ES2834490T3/es active Active
- 2016-06-15 KR KR1020187000829A patent/KR20180018684A/ko unknown
-
2018
- 2018-11-29 HK HK18115299.6A patent/HK1256199A1/zh unknown
-
2019
- 2019-04-04 US US16/375,047 patent/US10485806B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
US10485806B2 (en) | 2019-11-26 |
ES2834490T3 (es) | 2021-06-17 |
US10272095B2 (en) | 2019-04-30 |
CN108137557A (zh) | 2018-06-08 |
MA52032A (fr) | 2021-01-20 |
EP3766878B1 (en) | 2022-03-16 |
US20180169110A1 (en) | 2018-06-21 |
AU2016280236B2 (en) | 2019-02-07 |
ES2910938T3 (es) | 2022-05-17 |
KR20180018684A (ko) | 2018-02-21 |
RU2018101080A (ru) | 2019-07-15 |
JP6786527B2 (ja) | 2020-11-18 |
EP3307729A1 (en) | 2018-04-18 |
CN108137557B (zh) | 2021-09-07 |
EP3307729B1 (en) | 2020-09-02 |
RU2018101080A3 (zh) | 2019-07-17 |
WO2016203401A1 (en) | 2016-12-22 |
JP2018517730A (ja) | 2018-07-05 |
CA2988374A1 (en) | 2016-12-22 |
BR112017027137A2 (pt) | 2018-08-14 |
US20190224212A1 (en) | 2019-07-25 |
EP3766878A1 (en) | 2021-01-20 |
AU2016280236A1 (en) | 2017-12-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL256297B (en) | Regulators of nrf2 | |
HK1256199A1 (zh) | Nrf2調節劑 | |
ZA201707785B (en) | Beamforming | |
DK3256579T3 (en) | Cysteinprotease | |
DK3256580T3 (en) | Cysteinprotease | |
DK3250592T3 (en) | Anti-transthyretin-antistoffer | |
DK3284069T3 (en) | Pos-terminal | |
GB2555736B (en) | Fixing | |
DK3272750T3 (en) | Morphinan-derivat | |
AU361999S (en) | Ballustrade | |
GB201610183D0 (en) | Structure | |
GB201511225D0 (en) | Novel structure | |
PL3257657T3 (pl) | Struktura zapobiegająca wyciekaniu | |
DK3133099T3 (en) | Polymermodificeret polyoldispersion | |
DK3282866T3 (en) | Proteinfibre | |
GB201610190D0 (en) | Structure | |
DK3250312T3 (en) | Urea-metalnitrat-scr-system | |
DK3294653T3 (en) | Justerbar inline-port | |
ZA201807587B (en) | Polytunnel structure | |
DK3242882T3 (en) | Cgrp-antagonistpeptider | |
GB201514625D0 (en) | Regulator | |
AU5516P (en) | LEP08 Lepidosperma squamatum | |
AU5511P (en) | PTK647 Epichloe coenophiala | |
GB201520684D0 (en) | Aeroplanes | |
AU366552S (en) | Nutblock |